Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bethesda, Maryland


Purpose:

The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment recurrent malignant gliomas.


Criteria:

Inclusion Criteria: - Patient must be at least 18 years old - Patient must have been diagnosed with a recurrent brain tumor by MRI scan - Patient must be willing to practice adequate contraception - Patient must be able to swallow the Enzastaurin tablets whole and receive Bevacizumab intravenously - Patient must agree to use the study drug only as instructed by your study doctor and staff. Exclusion Criteria: - Women who are pregnant or breastfeeding - Patients who have significant heart, liver, kidney, or psychiatric disease - Patients who have an active infection - Patients who have any recent bleeding in the brain - Patients who are taking any anti-coagulation or anti-platelet medication (including aspirin, non-steroidal anti-inflammatories, COX-2 inhibitors)


NCT ID:

NCT00586508


Primary Contact:

Study Director
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company


Backup Contact:

N/A


Location Contact:

Bethesda, Maryland
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.